Allen Lutz

Ron declined to quantify the 2Q margin benefit, emphasizing own-brand/specialty/tech mix and gross-profit dollars over margin percentage.

Ron said share gains are broad-based rather than category-specific, driven by own-brand growth outpacing branded portfolio and continued momentum from 2025 promotional activity that retained customers and increased share of wallet.

Ron confirmed no unusual pricing dynamics in implants, with growth driven by execution and market share gains rather than pricing. Stanley noted premium brand Camlog has stable pricing in Germany with continued share gains.

Ron cited continued value implant volume growth for gross profit dollar expansion, potential premium implant recovery, steady endodontic contributions, and orthodontics becoming a more positive contributor in 2026. Stanley added that specialty group is doing significant value creation work on consolidating offices, facilities, and manufacturing.

Stanley described DSOs as stable to positive with available funding. Ron added that new office design projects showed double-digit year-over-year growth every month except May, which had double-digit negative growth reflecting tariff uncertainty.

Ron said glove pricing has stabilized with sequential improvement expected, but year-over-year comparisons will still show slightly lower distribution gross margins. Technology and specialty product mix provide overall margin lift.

Stanley attributed weakness to consumer sentiment for high-end procedures, noted value implants more stable than premium. Tapered Pro Conical and SmartShape Healers well received but did not provide specific growth rates.

Stanley confirmed build-outs are increasing versus 2024, driven by DSOs and smaller/regional practices adjusting to current interest rate levels. Noted well-financed DSOs are investing again.

Ron described relative regional dynamics but did not provide specific growth rates. Said the MA coverage change has not had a material attributable impact.

Stanley explained that specialty segment margins include lower-margin businesses like handpiece repair and corporate brand management costs, diluting the higher-margin implant and endo lines.

CFO confirmed generics were a positive profit driver in the quarter and year and expected to benefit FY2027 profit as well, while revenue was variable through the year given IRA WAC changes, moderating GLP volumes, and LOE shifts.

CFO attributed FCF strength to broad-based working capital management across all businesses, not any single factor. Also clarified pharma revenue dynamics with IRA WAC and GLP-1 mix offsets.

Jason attributed brand growth to years of investment in manufacturing capacity, service levels at all-time highs, backorders at all-time lows. Constraints largely removed enabling new customer/category expansion. Aaron noted GMPD SG&A actually declined year-over-year from optimization efforts consistent with five-point improvement plan.

Aaron attributed growth to clinically differentiated products: compression, electrocardiography, surgical kitting, syringes. Part of GMPD 5-point improvement plan. Continued investment planned in these areas.

Aaron emphasized gross margin also improved. SG&A increase primarily driven by ION, GIA, and ADS acquisition inclusion. Organic SG&A up only 4%. Synergy opportunities expected to develop over time.

Jason noted no script headwinds visible, even in first month of next quarter. Industry historically resilient through macro events including the Great Recession.

Aaron declined to give specific COVID profit number but confirmed it was a modest headwind, exactly as expected. Overcame it with strong underlying performance.

Jason emphasized they manage on gross margin dollars, not rate. Model unchanged, gross margin dollars growing faster than SG&A is what matters.

Eva said the Q2-to-Q3 acceleration was driven by underlying utilization strength, and Q4 implied guidance also implies strong double-digit growth with the OneOncology customer loss fully lapped and an easier expense comp. Bob said the ramp was mechanical, not aspirational, and that 340B guidance is still being assessed.

Jim confirmed that adding back $10M weather and $10M COVID headwinds would have put OI $20M higher with a higher growth rate. Did not address oral GLP-1 profitability shift specifically.

Jim reiterated same core drivers: utilization trends, specialty sales to health systems and physician practices, broad-based performance. Range width reflects level of strong performance against increasingly tough comps.

Jim confirmed specialty is accretive to OI growth and will continue to be. Generic deflation moderation trends continue. Contracts rebalanced for fair returns across brand, specialty, and generic. Did not quantify specific growth rates.

Bob declined to break out vertical-specific growth but confirmed broad-based specialty performance across all sites of care. Highlighted health systems alongside community practices. Jim added US OI guidance raised 3pp at both ends.

Jim noted strong utilization in Q1 continuing from FY24. The 2pp guidance range is primarily driven by varying utilization assumptions for the balance of the year.

Laz confirmed GLP-1s drove the acceleration (55% YoY, 14% sequential) alongside continued strong growth rates in specialty distribution.

Britt explained 3PL variability drives revenue swings while operating profit growth at upper end of LRP reflects strong access program demand including GLP-1s.

Brian described AI, large language models, and tech tools improving internal workflows to automate email processing and agent queuing, delivering a big productivity boost. Britt noted RxTS operating margins grew over 130 bps YoY with continued automation of biopharma services.

Britt attributed OpEx decline to Rexall divestiture impact, more favorable business mix, and efficiency from technology/AI modernization. Brian added these are manifestations of multi-year investments in physical and digital automation.

Britt confirmed brand pricing and generics environment in line with expectations. Brian added tariff impacts represented in guidance and pharmaceutical supply chain has sufficient inventory to navigate.

Brian stated urgency has been consistent for years but execution depends on finding transactions that clear financial discipline hurdles. Britt added this is consistent with multi-year portfolio realignment strategy.

Britt explained multi-year focus on operating leverage through automation and data analytics, while continuing to invest in growth areas like RxTS.

Britt emphasized both cost and increasingly supply/service levels through ClarusONE, without P&L specifics.